AKCA Akcea Therapeutics Inc.

18.1
-1.05  -5%
Previous Close 19.15
Open 19.13
Price To Book 5.22
Market Cap 1,824,021,744
Shares 100,774,682
Volume 396,818
Short Ratio
Av. Daily Volume 300,189
Stock charts supplied by TradingView

NewsSee all news

  1. Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx

    BOSTON and CARLSBAD, Calif., Jan. 22, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today announced

  2. Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

    BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced

  3. New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease

    Patients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study underway

  4. Akcea Retains Rights to AKCEA-APOCIII-LRx

    BOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today

  5. Akcea Therapeutics Announces New Appointments to its Board of Directors

    BOSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointments of Lynne Parshall, J.D., as chair of the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Pilot study data due mid-2019.
AKCEA-ANGPTL3-LRx
Rare hyperlipidemias
Phase 2 data due early 2020.
AKCEA-ANGPTL3-LRx
Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus
Phase 2 data met primary and secondary endpoints - January 22, 2020.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
Phase 3 trial to be initiated 2H 2019.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
CRL issued August 27, 2018.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 3 initiated November 2015
Volanesorsen
Partial lipodystrophy rapidly
Phase 3 data met primary endpoint - August 6, 2019.
Volanesorsen
Familial partial lipodystrophy (FPL)
Phase 3 trial initiation announced November 25, 2019.
AKCEA-TTR-LRx
hATTR Amyloidosis
Phase 3 trial initiation announced January 10, 2020.
AKCEA-TTR-LRx - CARDIO-TTRansform
ATTR cardiomyopathy

Latest News

  1. Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx

    BOSTON and CARLSBAD, Calif., Jan. 22, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today announced

  2. Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

    BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced

  3. New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease

    Patients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study underway

  4. Akcea Retains Rights to AKCEA-APOCIII-LRx

    BOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today

  5. Akcea Therapeutics Announces New Appointments to its Board of Directors

    BOSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointments of Lynne Parshall, J.D., as chair of the

  6. Akcea Announces Appointment of New Chief Operating Officer

    BOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company as chief operating

  7. Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis

    BOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today

  8. Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today

  9. Akcea Therapeutics to Present at Upcoming Investor Conferences

    BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with

  10. Akcea Reports Financial Results and Highlights for Third Quarter 2019

    Reported Third Quarter 2019 Global Net Product Revenues of $12 Million WAYLIVRA® (volanesorsen) launched in the E.U. Entered into a worldwide licensing agreement with Pfizer, Inc. for AKCEA-ANGPTL3-LRx Conference Call

  11. Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day

    BOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), today recognizes Familial Chylomicronemia Syndrome (FCS)

  12. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx

    Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive

  13. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that

  14. Akcea Announces CEO Transition and Elects Two New Board Members

    BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed Damien McDevitt,

  15. Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting

    Data show >90% knockdown of TTR following administration in healthy volunteers Positive safety and tolerability profile for LICA platform-based therapy Phase 3 program on track to start later this year in patients

  16. Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings

    Multiple presentations on the long-term efficacy and safety of TEGSEDI® (inotersen) in patients with polyneuropathy caused by hATTR Amyloidosis Topline data results to be presented from the Phase 1 study of